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Abstract
Ubiquitination, a post-translational modification, mediates diverse cellular functions including endocytic transport of
molecules. Kaposi’s sarcoma-associated herpesvirus (KSHV), an enveloped herpesvirus, enters endothelial cells primarily
through clathrin-mediated endocytosis. Whether ubiquitination and proteasome activity regulates KSHV entry and
endocytosis remains unknown. We showed that inhibition of proteasome activity reduced KSHV entry into endothelial cells
and intracellular trafficking to nuclei, thus preventing KSHV infection of the cells. Three-dimensional (3-D) analyses revealed
accumulation of KSHV particles in a cytoplasmic compartment identified as EEA1+ endosomal vesicles upon proteasome
inhibition. KSHV particles are colocalized with ubiquitin-binding proteins epsin and eps15. Furthermore, ubiquitination
mediates internalization of both KSHV and one of its receptors integrin b1. KSHV particles are colocalized with activated
forms of the E3 ligase c-Cbl. Knock-down of c-Cbl or inhibition of its phosphorylation reduced viral entry and intracellular
trafficking, resulting in decreased KSHV infectivity. These results demonstrate that ubiquitination mediates internalization of
both KSHV and one of its cognate receptors integrin b1, and identify c-Cbl as a potential E3 ligase that facilitates this
process.
Citation: Greene W, Zhang W, He M, Witt C, Ye F, et al. (2012) The Ubiquitin/Proteasome System Mediates Entry and Endosomal Trafficking of Kaposi’s Sarcoma-
Associated Herpesvirus in Endothelial Cells. PLoS Pathog 8(5): e1002703. doi:10.1371/journal.ppat.1002703
Editor: Pinghui Feng, University of Texas-Southwesten Medical school, United States of America
Received July 1, 2011; Accepted March 30, 2012; Published May 17, 2012
Copyright:  2012 Greene et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits
unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Funding: This study was supported in part by Public Health Service Grants CA096512, CA124332, and CA119889 to S.J.G.. W.G. was supported by a COSTAR
training grant NIDCR T-32 DE14318. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.
Competing Interests: The authors have declared that no competing interests exist.
* E-mail: shoujiag@usc.edu
. These authors contributed equally to this work.
Introduction
Ubiquitination has been linked to diverse cellular functions
including directing protein recycling [1,2]. Addition of four or
more ubiquitin moieties (polyubiquitination) provides the neces-
sary signal for targeting protein for proteasomal degradation.
Ubiquitination of target cell surface membrane proteins triggers its
internalization and endocytic sorting in addition to proteasomal
degradation. For examples, monoubiquitination, the addition of
single ubiquitin moieties, of epidermal growth factor receptor
(EGFR) cytoplasmic tail induces its internalization and transport
to the lysosome for degradation [3–5] while ubiquitination of
membrane receptors b2 adrenergic receptor and interleukin 2
receptor b chain is required for their correct internalization and
processing [6–8].
The two arms of the ubiquitin/proteasome system are separate,
yet closely linked [9]. Ubiquitination is initiated by the conjugation
of two ubiquitin molecules to the E1 activating enzyme. The
ubiquitin molecules are then transferred to the E2 conjugating
enzyme in an ATP-dependent reaction. E2 enzyme interacts with
a specific E3 partner and transfers the ubiquitin molecules to the
target protein [9]. The ubiquitinated proteins are subsequently
transported to the proteasome where the ubiquitin chains are
cleaved off by deubiquitinating enzymes (DUBs) releasing the
ubiquitin molecules to reenter the cycle [2]. Mammalian cells
express two E1 activating enzymes, up to 40 E2 conjugating
enzymes, and hundreds of E3 ligases [10,11].
Kaposi’s sarcoma-associated herpesvirus (KSHV) primarily
utilizes the clathrin-mediated endocytosis pathway to enter host
cells [12,13]. KSHV is a large enveloped DNA virus that uses cell
surface molecules as its receptors, which includes heparan sulfate
[14], integrin a3b1 [15], integrin a6b3 [16], xCT [17] and DC-
SIGN [18], to initiate entry into target cells. The possible role of
the ubiquitin/proteasome system during the internalization of
KSHV and its cognate receptor(s) has yet to be examined. In this
study, we investigated the role of the ubiquitin/proteasome system
during the entry and intracellular trafficking of KSHV and one of
its cognate receptors, integrin b1. We detailed the requirements
for proteasome function and de novo ubiquitination for efficient
viral entry into endothelial cells and intracellular trafficking to the
perinuclear regions. Inhibition of proteasome function by several
chemicals reduced viral entry and intracellular trafficking, and
caused an accumulation of viral particles in an early endosomal
compartment. As a result, KSHV infectivity was reduced.
PLoS Pathogens | www.plospathogens.org 1 May 2012 | Volume 8 | Issue 5 | e1002703Inhibition of proteasome function resulted in an enrichment of
ubiquitinated proteins and a depletion of the cellular pool of free
ubiquitin. Inhibition of E1 activating enzyme reduced internali-
zation of KSHV as well as its receptor integrin b1. The E3 ligase
c-Cbl was activated during KSHV entry. Knock-down of c-Cbl or
inhibition of its activation blocked KSHV entry and intracellular
trafficking, resulting in reduced viral infectivity, suggesting that this
E3 ligase may mediate the internalization, and endosomal
transport and sorting of KSHV-containing endosomes. We also
report the involvement of the E3 ligase Rabex5, and the endocytic
adaptor proteins epsin and eps15, during KSHV entry into
endothelial cells. These results suggest that ubiquitination is
required for KSHV entry into endothelial cells and during its
endosomal sorting and intracellular trafficking.
Results
Inhibition of Proteasome Function Reduces KSHV Entry
into Endothelial Cells and Intracellular Trafficking to Nuclei
To investigate the role of proteasome activity during KSHV
entry and intracellular trafficking, primary human umbilical vein
endothelial cells (HUVEC) were pretreated with chemical
inhibitors of the 26S proteasome, MG132 or epoxomicin (EPOX),
for 1 hr prior to KSHV infection. MG132 is a peptide aldehyde
that potently inhibits the transition state of the proteasome [19].
EPOX selectively and irreversibly binds to the catalytic b subunits
of the proteasome and effectively inhibits multiple proteolytic
activities [20]. At 4 hr post-infection (hpi), the total numbers of
viral particles docked at each nucleus or in a whole cell revealed by
staining for small capsid protein Orf65 were quantified. Inhibition
of proteasome activity with either MG132 or EPOX had no effect
on the total numbers of cell-associated viral particles including
those that were associated with plasma membrane (Figure S1),
indicating that the proteasome inhibitors do not affect the
attachment of viral particles to the cells. However, inhibition of
proteasome activity with either MG132 (Figure 1A–B) or EPOX
(Figure 1C–D) resulted in significantly fewer Orf65+ viral particles
docked at the nuclear membranes at a dose-dependent fashion
compared to cells treated with DMSO alone. Under these
experimental conditions, we did not observe any noticeable
cytotoxicity of the inhibitors to the cells based on propidium
iodide (PI) staining (data not shown). To determine whether
proteasome inhibitors actually blocked the infectious pathway of
KSHV entry and intracellular trafficking, we stained the cells for
the expression of LANA protein (Orf73) for evidence of successful
infection. Inhibition of proteasome function significantly reduced
the numbers of LANA-positive cells at 48 hpi (Figure 2A and B).
At the highest used doses of MG132 (96 mg/ml) and EPOX
(500 nM), LANA-positive cells were reduced from 96.86% of the
untreated cells to 0% and 3.49%, respectively (Figure 2B). These
results indicate that proteasome activity is necessary for successful
KSHV intracellular trafficking to the nuclei.
We next sought to identify where viral particles were trapped in
cells treated with proteasome inhibitors. HUVEC were pretreated
with the indicated inhibitors for 1 hr and then inoculated with
KSHV in the presence of the inhibitors. At 4 hpi, cells were
stained for viral capsids (Orf65) in red, the cell membrane
(AlexaFluor 647 WGA) in white, and nuclei (DAPI) in blue.
Confocal laser-scanning microscopy was used to acquire Z-stack
images. Deconvolved images were analyzed in three-dimensional
(3-D) to determine the numbers of viral particles in the
extracellular, membrane-bound, cytoplasmic, or nuclear spaces.
The spot detection function was used to identify and quantify the
number of Orf65+ viral particles in a cell. Surface contours were
generated to enable the visualization of cell membranes and nuclei
(Figures 3A–C, and Videos S1–S4). There is a modest but
statistically significant increase in the numbers of viral particles
retained at the plasma membranes following proteasome inhibi-
tion (Figure 3D). In addition, a greater proportion of viral particles
were retained in the cytoplasm in the proteasome-inhibited cells
compared to untreated cells (Figure 3E). As expected, fewer viral
particles reached the nuclear membrane (Figure 3F).
The increased number of viral particles in the cytoplasm suggests
that inhibition of proteasome activity might lead to an arrest in the
maturation of viral particle-containing endosomes. To identify the
specific cellular compartment where the viral particles were
arrested, HUVEC were inoculated with KSHV and fixed at
4 hpi. In addition to Orf65+ viral particles, cells were stained for
eitherEEA1(Figure4,and VideosS5–S8)orLAMP1(Figure5,and
VideosS9–S12) to identify the early endosomal compartment or the
late endosome/lysosomal compartment, respectively. Confocal z-
stack images were acquired and subjected to 3-D colocalization
analysis. Proteasome inhibition resulted in more viral particles
colocalized with the early endosome marker, EEA1, in the entire
cells (Figure4B), or viralparticlesassociated with plasma membrane
(Figure 4C) and cytoplasm (Figure 4D), compared to untreated
controls. In contrast, fewer viral particles were colocalized with
LAMP1, the late endosome/lysosome marker, in the entire cells
(Figure 5B), or viral particles associated with plasma membrane
(Figure 5C) and cytoplasm (Figure 5D), following proteasome
inhibition. These results suggest that proteasome function is
required for the maturation of virus-containing endosomes from
the early to late endosome, and that endosomal maturation is
necessary for successful viral trafficking to nuclei.
KSHV Particles Are Colocalized with Ubiquitin-Binding
Proteins during Internalization
Proteasome function per se may not directly regulate internal-
ization of KSHV particles. Inhibition of proteasome function
Author Summary
Ubiquitination, a post-translational modification, mediates
important cellular functions including endocytic transport
of molecules. Kaposi’s sarcoma-associated herpesvirus
(KSHV) is a gammaherpesvirus linked to the development
of Kaposi’s sarcoma, an endothelial malignancy commonly
found in AIDS patients, and several other malignancies.
KSHV enters endothelial cells primarily through clathrin-
mediated endocytosis. In this study, we show that the
proteasome activity is required for KSHV entry into
endothelial cells and intracellular trafficking to nuclei.
Inhibition of proteasome activity reduced KSHV infectivity
and led to the accumulation of KSHV particles in EEA1+
early endosomal vesicles. Furthermore, we show that
ubiquitination mediates the internalization of both KSHV
and one of its receptors integrin b1. KSHV particles are
colocalized with ubiquitin-binding proteins epsin and
eps15, as well as activated forms of the E3 ligase c-Cbl.
Knock-down of c-Cbl or inhibition of its phosphorylation
blocked KSHV entry and trafficking, thus preventing KSHV
infection of endothelial cells. Together, these results
illustrate the essential role of ubiquitination during the
internalization of KSHV and its cognate receptor integrin
b1. The identification of an E3 ligase that mediates the
ubiquitination of KSHV and its cognate receptor integrin
b1 leading to viral entry provide a potential therapeutic
target for this oncogenic virus.
Ubiquitin/Proteasome System Regulates KSHV Entry and Trafficking
PLoS Pathogens | www.plospathogens.org 2 May 2012 | Volume 8 | Issue 5 | e1002703results in the accumulation of ubiquitinated proteins, which may
reduce the pool of free ubiquitin available for de novo ubiquitination
events, implying that ubiquitination of KSHV and/or its receptors
could be the mediator of KSHV internalization. To further
understand how proteasome inhibition prevents viral entry and
intracellular trafficking, we investigated the role of two adaptor
molecules that link clathrin-mediated endocytosis and ubiquitina-
tion. Epsin and Eps15 are endocytic adaptor proteins that
recognize ubiquitinated cargo through their ubiquitin-interacting
motifs (UIMs) [21,22]. Binding of Epsin to ubiquitinated EGFR is
required for its translocation into clathrin-coated pits [22]. Binding
of Eps15 to ubiquitinated Cx43 mediates its internalization
through endocytosis [21]. Since KSHV enters HUVEC primarily
through clathrin-mediated endocytosis, we hypothesized that
endocytic adaptor proteins such as Epsin or Eps15 may play an
important role during KSHV entry. As shown in Figure 6A, most
KSHV particles were colocalized with both Epsin and Eps15
during infection of HUVEC. However, we also observed small
numbers of KSHV particles that were not colocalized with the
adaptor proteins, possibly reflecting the transient nature of the
interaction. The detection of these non-colocalized particles
indicates that the observed colocalization is specific but not due
to random distribution of the viral particles. These results suggest
that KSHV utilizes clathrin-mediated endocytosis to enter cells,
and either KSHV or its receptor(s) is subjected to ubiquitination
during the viral internalization process.
Inhibition of Proteasome Function Depletes the Cellular
Pool of Free Ubiquitin
Although the proteasome primarily functions as a protein
degradation system, inhibition of its functions has deleterious
effects on many other cellular activities, including endocytosis
[23,24]. We hypothesized that inhibition of proteasome function
results in an accumulation of ubiquitinated proteins and thus a
reduction in the cellular pool of ubiquitin monomers available for
de novo ubiquitination reactions. To test this, we treated endothelial
cells with either MG132 or EPOX for 1 hr, before the inoculation
with KSHV. Cells were analyzed for ubiquitin by immunoblots at
different times post-treatment. Both polyubiquitinated proteins
and free ubiquitin were detected in the DMSO-treated samples
Figure 1. Inhibition of proteasome activity prevents KSHV entry into endothelial cells and intracellular trafficking to nuclei. (A and
C) HUVEC were treated with proteasome inhibitors MG132 (A) and EPOX (C) at indicated doses for 1 hr. Cells were then infected with KSHV in the
presence of the inhibitors, fixed at 4 hpi, and stained for Orf65+ viral particles (red) and nuclei (blue). (B and D) Quantification of the total number of
Orf65+ particles docked at each nucleus following treatment with proteasome inhibitors MG132 (B) and EPOX (D).
doi:10.1371/journal.ppat.1002703.g001
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higher molecular weight ubiquitinated proteins was visible in all
lysates tested, though there was an obvious increase in the amount
of ubiquitination in the samples treated with proteasome
inhibitors. However, low molecular weight free ubiquitin was
not detected in samples treated with proteasome inhibitors,
indicating that inhibition of proteasome function reduces the
availability of ubiquitin monomers.
Ubiquitination Is Required for Internalization of KSHV
Receptor Integrin b1
Integrin a3b1 is one of the cellular receptors for KSHV entry
into cells [15]. As expected, 3-D colocalization analysis revealed
significant levels of colocalization between KSHV particles with
integrin b1 (Figure 7A). To determine the specificity of the
observed colocalization, we examined the colocalization of
integrin b1 with transferrin, cholera toxin B and rhesus
rhadinovirus, all of which enter cells by endocytosis without using
integrin b1 as a receptor [25,26]. In contrast to the perfect
colocalization of KSHV, less than 10% of RRV, transferrin or
cholera toxin B was colocalized with integrin b1 (Figure S2).
Integrins are transmembrane glycoproteins composed of a and
b chains. Integrins are constitutively endocytosed and recycled
[27,28]. While integrins are ubiquitinated [29], the role of
ubiquitination in integrin endocytosis is not well understood. As
a known receptor for KSHV entry into cells, we hypothesized that
ubiqutination regulates the internalization of integrin b1 and
KSHV. UBEI-41 is an inhibitor of the E1 activating enzyme that
potently and specifically blocks the first step of the ubiquitination
reaction [30]. Uninfected cells had low level of ubiquitinated
integrin b1, which was significantly increased following KSHV
infection (Figure 7B). Treatment with UBEI-41 almost completely
abolished the level of ubiquitinated integrin b1 in both uninfected
and KSHV-infected cells.
To further understand the role of ubiquitination during the
internalization of integrin b1, we labeled live cells with a
monoclonal antibody against integrin b1 to track its internalization
from the plasma membrane. As shown in Figure 7C, integrin b1
was internalized and localized to the perinuclear region in
untreated cells. Following treatment with UBEI-41, it was retained
at the plasma membrane (Figure 7D), suggesting integrin b1
internalization requires ubiquitination.
Inhibition of E1 Activating Enzyme Inhibits KSHV Entry
and Intracellular Trafficking in Endothelial Cells
The results from Figure 6B suggest that depletion of free
ubiquitin upon inhibition of proteasome function may be the
mechanism that inhibits the entry and intracellular trafficking of
KSHV particles. Since inhibition of E1 activating enzyme activity
prevents integrin b1 internalization, we expect KSHV entry and
intracellular trafficking to be also affected. Indeed, inhibition of E1
activating enzyme and ubiquitination reduced the number of viral
particles that successfully entered the cells and trafficked to the
nuclei (Figure 7E–F). However, UBEI-41 had no detectable effect
on the total numbers of viral particles per cell including those that
were associated with plasma membrane (Figure S1). Thus, the
inhibitor did not affect the attachment of viral particles to the cells.
PI staining did not detect any cytotoxicity to the cells at all the
concentrations used (data not shown). Together, these results
indicate that ubiquitination is required for efficient viral entry and
intracellular trafficking.
The Role of E3 Ligases c-Cbl and Rabex5 in KSHV Entry
and Intracellular Trafficking
E3 ubiquitin ligases are the final effectors in the ubiquitination
cascade. E3 ligases contain the substrate recognition motifs that
provide the target specificity for ubiquitination. Approximately
1,000 E3 ligases have been identified in humans. Among them,
Rabex5 is an E3 ligase involved in endocytosis and endosomal
maturation by specifically targeting Rab5-positive early endo-
somes [31,32] while the E3 ligase c-Cbl ubiquitinates integrin
complexes [33]. c-Cbl is activated through phosphorylation by the
Src family kinases principally at tyrosine residues 700, 731, and
774 [34–36]. Thus, Rabex-5 and c-Cbl are candidate E3 ligases
that may potentially mediate KSHV internalization. We therefore
sought to investigate the roles Rabex-5 and c-Cbl in KSHV entry
into endothelial cells. As shown in Figure 8A–B and Figure S3,
only a minimal amount of KSHV particles (6%) were colocalized
with Rabex5 during KSHV infection. In contrast, a significant
fraction of KSHV particles (70%) were colocalized with c-Cbl.
Furthermore, KSHV particles were also colocalized with two
activated phosphorylated forms of c-Cbl, at 40% with phospho-
tyrosine 700, and at 25% with phospho-tyrosine 774.
To directly examine the role of c-Cbl in KSHV entry and
intracellular trafficking, we performed loss-of-function analyses.
Knock-down of c-Cbl significantly reduced the number of KSHV
particles that successfully entered the cells and trafficked to the
nuclei (Figure 9A–C). In contract to c-Cbl, knock-down of Rabex-
5 had no effect on KSHV entry and intracellular trafficking
(Figure 9A–C). Consistent with these results, knock-down of c-Cbl
but not Rabex-5 almost completely abolished KSHV infectivity as
shown by the numbers of LANA-positive cells at 48 hpi (Figure 9D
and Figure S4).
c-Cbl is activated through phosphorylation by the Src family
kinases, and Src activity can be blocked by chemical analogs of
protein phosphatase 1 (PP1) [37], which inhibits the E3 ligase
activity of c-Cbl [38]. As expected, treatment of HUVEC with
increasing doses of PP1 analog inhibited viral entry and
intracellular trafficking, resulting in significantly fewer KSHV
particles reaching the nuclei (Figure 10A–B). Under these
experimental conditions, we did not observe any cytotoxicity to
the cells based on PI staining (data not shown). To verify that PP1
treatment prevents c-Cbl phosphorylation, immunoblot analysis
on HUVEC lysates collected following treatment with PP1 was
performed (Figure 10C). Exposure of cells to either 100 ng/ml
EGF or KSHV increased c-Cbl phosphorylation at tyrosines 700
and 774; however these phosphorylation modifications were
abrogated in the presence of PP1 analog.
Figure 2. Inhibition of proteasome activity reduced KSHV infectivity in endothelial cells. (A) Proteasome inhibitors MG132 and EPOX
reduced the numbers of LANA-positive cells. HUVEC grown on coverslips were pretreated with proteasome inhibitors for 1 hr and infected with KSHV
for 4 hr in the presence of the inhibitors. Cells were fixed and stained for LANA (red) and nuclei (blue) at 48 hpi. (B) Analyses of LANA-positive cells
following treatment with proteasome inhibitors depicted as box and whisker plots. Open boxes indicate the 75th and 25th percentiles. Top and
bottom short lines indicate the 90th and 10th percentiles, respectively. Middle lines in the boxes indicate the medians, also shown in ‘‘%’’ on tops.
Outliers outside the 90th and 10th percentiles are represented as black dots. Some elements of the box and whisker plots are missing because of
overrepresentation at lower or higher percentiles. ‘‘n’’ represents total number of fields analyzed per sample. p-values ,0.05 are statistically
significant.
doi:10.1371/journal.ppat.1002703.g002
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Our results clearly demonstrate the essential roles for both
ubiquitination and proteasome functions during KSHV entry and
intracellular trafficking in endothelial cells. Although it is the first
time shown for KSHV infection, the ubiquitin/proteasome system
is known to regulate either entry or gene expression of several
other viruses, including equine infectious anemia virus [39],
influenza virus [40,41] herpes simplex 1 [42], murine coronavirus
[43], and vaccinia virus [44]. We have found that the total
numbers of KSHV particles reaching nuclei were significantly
reduced upon suppression of proteasome function, suggesting that
virus entry and intracellular trafficking was arrested at a step prior
to docking at nuclei. Consistent with these results, we found that
proteasome inhibitors reduced KSHV infectivity indicating that
they indeed affected the KSHV infectious pathway. Three-
dimensional analysis of infected cells revealed that inhibition of
proteasome activity resulted in a modest increase in viral particles
retained at the plasma membrane, and a significant accumulation
of viral particles in the cytoplasm. Furthermore, cells treated with
proteasome inhibitors had increased numbers of viral particles
retained in the EEA1+ early endosomal compartments. Cells
treated with proteasome inhibitors had higher numbers of EEA1+
particles at the membrane, and higher numbers of EEA1+
particles in the cytoplasm as compared to cells treated with
DMSO. In contrast, proteasome inhibition reduced the total
number of KSHV particles in the LAMP1+ late endosome/
lysosome compartments. Lower numbers of LAMP1+ particles
were observed both in the cytoplasm and perinuclear regions.
These results are in agreement with the study conducted with
influenza virus, which showed that proteasome activity is required
for progress from the early to late endosomes during its entry of
cells [40].
While the proteasome system is required for the entry and
intracellular trafficking of several viruses [39–44], the mechanism
that mediates this process remains unclear. One of the primary
functions of proteasome is degradation of proteins, an intracellular
event. For viruses that enter cells via endocytosis, the entry process
is initiated by the attachment of infectious virions to the cellular
receptors at the surface of the cell followed by internalization of
viral particles and receptors. How proteasome function affects the
internalization and intracellular trafficking of virions from outside
the cell to the nuclei is not immediately obvious. However, it is
known that internalization of EGFR and other membrane
receptors requires the ubiquitination of the cytoplasmic tail.
Following ubiquitination, endocytic adaptor proteins Epsin and
Eps15 will recognize the ubiquitinated region of EGFR and
facilitate its movement into the clathrin-coated pits. Since KSHV
enters cells primarily through clathrin-mediated endocytosis
[12,13], we hypothesized that Epsin and or Eps15 are involved
in the entry process. Indeed, 3-D colocalization analysis revealed
that both Epsin and Eps15 are associated with KSHV particles,
suggesting that either the viral particles or their receptors are
ubiquitinated. In addition, when proteasome function is inhibited,
the level of free ubiquitin is greatly diminished, which may explain
how virus internalization and intracellular trafficking are sup-
pressed in this context.
Viral particles require cellular structures and processes to enter
cells, and specific membrane-bound receptors to facilitate their
attachment, internalization, and trafficking through the intracel-
lular space to the final destination. KSHV has evolved to use
members of the integrin family, mainly integrin a3b1 and integrin
avb3 as its receptors [15,16]. Integrins are heterodimers composed
of a and b subunits. We observed a high percentage of
colocalization of KSHV particles with integrin b1. Integrin b1i s
targeted for ubiquitination following inoculation with KSHV,
which is prevented by treatment with an inhibitor of the E1
activating enzyme. In addition, live-labeling of cells with antibody
against integrin b1 revealed that when ubiquitination is prevented,
integrin b1 is retained at the plasma membrane. Finally, entry and
intracellular trafficking of KSHV was greatly reduced in
endothelial cells treated with the inhibitor of E1 activating
enzyme, UBEI-41, in a dose-dependent manner, proving that
ubiquitination itself directly mediates viral entry and trafficking.
Together these results indicate that inhibition of proteasome
function causes an arrest at an early stage of KSHV entry into
cells, which is supported by the observations of increased numbers
of viral particles at the membrane and cytoplasm, and increased
colocalization of viral particles with EEA1. These results suggest
that ubiquitination may be required for the initial steps of
internalization from the plasma membrane and maturation of the
early endosome. In fact, ubiquitination may be required at
multiple steps of the entry process, from the formation of the
clathrin-coated pits and internalization, to endosomal maturation,
and finally docking at the nuclear membrane. Further studies
should delineate the possible roles for ubiquitination during post-
early endosome stages.
We have examined E3 ligases that may mediate KSHV
internalization and maturation of KSHV-containing endosomes.
EEA1 is a docking/tethering protein that binds to membranes
containing Rab5 GTPase, thus effecting endosomal fusion and
maturation [45–47]. Rab5 activation effected by GDP to GTP
conversion is regulated by a guanine nucleotide exchange factor
(GEF), Rabex-5. Rabex-5 is autoubiquitinated [48], and is also an
E3 ligase with a N-terminal ubiquitin-binding domain that
mediates cargo targeting to the early endosomal membrane
[31,49]. The fact that we have observed an accumulation of viral
particles in an EEA1+ early endosomal compartment in conditions
when ubiquitin is unavailable, as well as colocalization of viral
particles with Rabex-5 is intriguing. Although the level of
Figure 3. Cellular localization of KSHV particles following inhibition of proteasome activity. (A, B and C) HUVEC treated with DMSO (A),
MG132 (B) or EPOX (C) were incubated with KSHV for 4 hr, stained for viral particles (red), cell membrane (white) and nuclei (blue). Z-stack images
were acquired with confocal laser-scanning microscopy. Three-dimensional software was used to generate z-projection images (left column). Three-
dimensional contoured images (middle and right columns) were generated using Imaris image analysis software to determine the localizations of
KSHV particles in relation to the cell membrane, the cell interior, and the cell nucleus (upper panels). The 3-D images in the upper panels were rotated
on the x-axis to visualize viral particles attached at the cell membrane (small green arrows), internalized into the cytoplasmic space (orange triangles),
or docked at the nucleus (green triangles) (lower panels). Videos S1, S2, and S3 correspond to Figures 3A, B, and C respectively. Video S4 depicts viral
particles that have been engulfed, and are enclosed within a membrane-bound vesicle. (D–F) Quantification of cellular localization of cell-associated
KSHV particles as illustrated in A, B, and C, respectively. Box and whisker plots depict the statistical analyses of the cellular localization of KSHV
particles. Open boxes indicate the 75th and 25th percentiles. Top and bottom short lines indicate the 90th and 10th percentiles, respectively. Middle
thick lines in the boxes indicate the medians. Outliers outside the 90th and 10th percentiles are represented as black dots. To ensure representation,
only cells with at least five particles per cell were counted. The percentages of KSHV particles retained at the membrane for each sample are
illustrated in (D), the percentages of internalized KSHV particles in the cytoplasmic space are depicted in (E), and the percentages of KSHV particles
docked at the nuclei are illustrated in (F). ‘‘n’’ represents total number of cells analyzed per sample. p-values ,0.05 are statistically significant.
doi:10.1371/journal.ppat.1002703.g003
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PLoS Pathogens | www.plospathogens.org 7 May 2012 | Volume 8 | Issue 5 | e1002703Figure 4. Proteasome inhibitors increase KSHV particles associated with early endosomal marker EEA1. (A) HUVEC treated with DMSO,
MG132 or EPOX were incubated with KSHV for 4 hr, stained for viral particles (red), EEA1 (green), membrane (white), and nuclei (blue). Z-stacks were
deconvolved, and Imaris image analysis software was used to generate 3-D contoured images. Videos S5, S6 and S7 correspond to cells treated with
DMSO, MG132 or EPOX, respectively, labeled for KSHV particles and EEA1 rotated around the x-axis. Video S8 depicts KSHV particles enclosed in an
EEA1+ vesicle. (B–D) Imaris 3-D colocalization analyses determine the total numbers of KSHV particles in a cell that are colocalized with EEA1 (B), the
numbers of viral particles localized at cell membranes that are EEA1+ (C), and the numbers of viral particles localized within the cytoplasmic spaces
that are EEA1+ (D). Box and whisker plots depict the statistical analyses of the cellular localization of KSHV particles as described in Figure 3.
doi:10.1371/journal.ppat.1002703.g004
Ubiquitin/Proteasome System Regulates KSHV Entry and Trafficking
PLoS Pathogens | www.plospathogens.org 8 May 2012 | Volume 8 | Issue 5 | e1002703Figure 5. Inhibition of proteasome function reduces KSHV particles associated with late endosomal/lysosomal marker LAMP1. (A)
HUVEC treated with DMSO, MG132 or EPOX were incubated with KSHV for 4 hr, stained for KSHV particles (red), LAMP1 (green), membrane (white),
and nuclei (blue). Z-stacks were deconvolved and, Imaris image analysis software was used to generate 3-D contoured images. Videos S9, S10 and S11
correspond to cells treated with DMSO, MG132 or EPOX, respectively, labeled for KSHV particles and LAMP1 rotated around the x-axis. Video S12
depicts KSHV particles enclosed in an LAMP1+ vesicle. (B–D) Imaris 3-D colocalization analyses determine the total numbers of KSHV particles in a cell
that are colocalized with LAMP1 (B), the numbers of viral particles localized at cell membranes that are LAMP1+ (C), and the numbers of viral particles
localized within the cytoplasmic spaces that are LAMP1+ (D). Box and whisker plots depict the statistical analyses of the cellular localization of KSHV
particles as described in Figure 3.
doi:10.1371/journal.ppat.1002703.g005
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was unsynchronized, and the assay was performed at a single time
point, at 4 hpi. However, we did observe substantial colocalization
with the E3 ligase c-Cbl, and more specifically, we observed
colocalization with the activated phosphorylated forms of c-Cbl,
phospho-Y700 and phospho-Y774. Consistent with these results,
knock-down of c-Cbl significantly inhibited viral entry and
intracellular trafficking, and prevented KSHV infection of the
endothelial cells. Furthermore, when c-Cbl activation was
prevented by inhibition of Src, KSHV entry and intracellular
trafficking was dramatically reduced. Immunoblot analysis con-
firmed that Src inhibition did in fact prevent phosphorylation of c-
Cbl at tyrosine residues 700 and 774 during KSHV infection.
These results are in agreement with a recent study that
demonstrated the important role of c-Cbl tyrosine phosphorylation
for KSHV entry into human dermal microvascular endothelial
cells via the macropinocytic pathway [50]. The same group also
investigated the ubiquitination of myosin IIA during KSHV
infection, and found that c-Cbl may be mediating the formation of
membrane blebs through its E3 ligase activity. However, our
results have demonstrated the role of the ubiquitin proteasome
system during clathrin-mediated KSHV endocytic entry into
Figure 6. Association of KSHV particles with ubiquitin-interacting proteins during entry into endothelial cells. (A) Colocalization of
KSHV particles with Epsin and Eps15 during entry into HUVEC. HUVEC infected with KSHV for 1 hr were stained for viral particles (red) and ubiquitin-
interacting proteins (green) Epsin (top) or Eps15 (bottom). Images were analyzed in 3-D for colocalization of KSHV particles with Epsin or Eps15.
Regions of colocalization are depicted in yellow (second column). (B) Inhibition of proteasome function depletes the cellular pool of free ubiquitin.
HUVEC were treated with DMSO, MG132, or EPOX for 1 hr, and then infected with KSHV for 3 hr. Cell lysates were collected and analyzed by
immunoblotting to detect both low molecular weight free ubiquitin as well as ubiquitinated proteins (top panel). b-actin was used as a loading
control (bottom panel). Longer exposure shown on the left was used to detect the low molecular weight band corresponding to monomeric
ubiquitin at 7.5 kD. The shorter exposure shown at the right panel was used to illustrate relative levels of ubiquitinated proteins. (C) Quantification of
relative levels of ubiquitinated proteins detected in B.
doi:10.1371/journal.ppat.1002703.g006
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PLoS Pathogens | www.plospathogens.org 11 May 2012 | Volume 8 | Issue 5 | e1002703Figure 7. Ubiquitination mediates internalization of integrin b1 and KSHV entry and intracellular trafficking. (A) Colocalization of KSHV
particles with integrin b1 during entry into endothelial cells. HUVEC infected with KSHV were stained for viral particles (red) and integrin b1 (white).
Images were subjected to 3-D colocalization analysis. Regions of colocalization are depicted in green. (B) Increase of ubiquitination of integrin b1
following KSHV infection, which is blocked by UBEI-41. HUVEC pretreated with DMSO or UBEI-41 for 1 hr were infected with KSHV. At 1 hpi, integrin
b1 was immunoprecipitated and the ubiquitinated protein detected by Western-blotting. (C and D) Ubiquitination mediates internalization of
integrin b1. HUVEC pretreated with DMSO (C) or UBEI-41 (D) for 1 hr were labeled with a monoclonal antibody to integrin b1 for 1 hr, fixed and
labeled with an AlexaFluor488 goat anti-mouse antibody. Z-stack images were acquired to visualize the cellular location of the labeled integrin b1. (E)
Inhibition of E1 activating enzyme reduces KSHV entry and intracellular trafficking in endothelial cells. HUVEC were pretreated for 1 hr with UBEI-41
before infection with KSHV for 4 hr, and stained for viral particles (red) and nuclei (blue). (F) Quantification of the numbers of KSHV particles docked
at nuclei following inhibition with UBEI-41 as described in E.
Figure 8. Colocalization of KSHV particles with E3 ligases during KSHV entry and intracellular trafficking in endothelial cells. (A)
Most KSHV particles are colocalized with E3 ligase c-Cbl or its activated phosphorylated forms but, to a less extent, with Rabex5. HUVEC infected with
KSHV for 4 hr were stained for KSHV particles (red), E3 ligase Rabex5, c-Cbl or its phosphorylated forms (pY700 or pY774) (green), and cell nuclei
(blue). Z-stack images were acquired and used for colocalization analysis with the Imaris software. Regions of 3-D colocalization are depicted in
yellow. (B) Quantification of colocalization of KSHV particles with Rabex5, c-Cbl, phospho-Y700 c-Cbl and phospho-Y774 c-Cbl.
doi:10.1371/journal.ppat.1002703.g008
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mediator of KSHV entry into endothelial cells, confirming its
essential roles as both an adaptor molecule and as an E3 ligase in
clathrin-mediated endocytosis. Nevertheless, it remains possible
that ubiquitination and other E3 ligases are involved at later stages
of endosomal maturation. Mammalian cells express hundreds of
E3 ligases. The functions of most of these other ligases have not
been well-studied. The identification of an E3 ligase that
specifically mediates ubiquitination leading to viral entry could
certainly provide a potential therapeutic target.
Figure 9. Knock-down of c-Cbl but not Rabex-5 inhibits KSHV entry and intracellular trafficking, and prevents KSHV infection of
endothelial cells. (A) HUVEC mock-treated or infected with c-Cbl, Rabex-5 or control shRNA lentivirus particles for 4 days were examined for the
expression of c-Cbl, Rabex-5 and b-tubulin by Western-blotting. (B) HUVEC grown on coverslips were mock treated or infected with c-Cbl, Rabex-5 or
control lentivirus particles for 4 days, and infected by KSHV for 4 hr. Cells were stained for Orf65+ viral particles (red) and nuclei (blue). Knock-down
with c-Cbl shRNA but not Rabex-5 shRNA or control shRNA decreased the numbers of KSHV particles successfully docked at perinuclear regions. (C)
Analyses of numbers of KSHV particles docked on each nucleus following shRNA lentivirus infection depicted as box and whisker plots as described in
Figure 3. (D) Quantification of LANA-positive cells following KSHV infection for 48 hr in cells with prior knock-down with c-Cbl, Rabex-5, or control
shRNA (Figure S4). HUVEC grown on coverslips were mock treated or infected with lentivirus particles for 4 days, and infected by KSHV. At 48 hpi,
cells were stained for LANA (red) and nuclei (blue). LANA-positive cells were analyzed and depicted as box and whisker plots as described in Figure 2B.
c-Cbl shRNA but not Rabex-5 shRNA or control shRNA decreased the numbers of LANA-positive cells.
doi:10.1371/journal.ppat.1002703.g009
Figure 10. Inhibition of phosphorylation of E3 ligases reduces KSHV entry and intracellular trafficking in endothelial cells. (A)
Treatment with PP1 analog inhibits KSHV entry and intracellular trafficking in a dose-dependent manner. HUVEC pretreated with PP1 analog for 1 hr,
infected with KSHV for 4 hr, and stained for KSHV particles (red) and nuclei (blue). (B) Quantification of the total number of Orf65+ particles docked at
each nucleus following treatment with PP1 analog. (C) Treatment with PP1 analog prevents phosphorylation of c-Cbl during KSHV infection. HUVEC
pretreated with Src kinase inhibitor PP1 analog for 1 hr were infected with KSHV for 30 min. E3 ligase c-Cbl, phospho-Y700 c-Cbl, and phospho-Y774
c-Cbl were detected using b-actin as a loading control. EGF was used as a positive control for c-Cbl activation.
doi:10.1371/journal.ppat.1002703.g010
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Cell Culture, Viral Stock and Viral Infection
Early passage of HUVEC were obtained from Clonetics, Lonza
and maintained in complete EBM-2 culture media (Allendale, NJ).
KSHV-infected BCP-1 cells established from the peripheral blood
mononuclear cells of a PEL patient [51] were maintained in
culture in RPMI1640 containing 10% fetal bovine serum (FBS).
Doxycycline-inducible iSLK cells, provided by Dr. Jae Jung at the
University of Southern California, were maintained in DMEM
supplemented with 10% FBS, 250 mg/ml of G418, 1,200 mg/ml of
hygromycin, 1 mg/ml of puromycin, and 1% penicillin-strepto-
mycin solution.
To induce virus production from BCP-1 cells, cells grown to
log-phase were serum-starved overnight in RPMI1640. FBS was
added back to the culture media to a final concentration of 10%,
together with 12-O-tetradecanoyl-phorbol-13-acetate (TPA) at
30 ng/ml and sodium butyrate at 200 mM. At 2 days post-
induction, the cells were washed and the media was replaced with
fresh RPMI1640 containing 10% FBS without TPA or sodium
butyrate. The culture medium was collected at 6 days post-
induction. To obtain virus from iSLK cells, cells were induced
with 1 mg/ml doxycycline and 1 mM sodium butyrate in DMEM
supplemented with 10% FBS and the culture medium was
collected 4 days later. To concentrate virus, the culture medium
was centrifuged first at 5,0006g for 30 min to eliminate cell debris
and then passed through a 0.45-mm filter, followed by centrifu-
gation at 100,0006g for 3 h. The final pellet was dissolved in the
culture medium overnight and was adjusted to a desired volume.
Undissolved debris was eliminated by centrifugation at 5,0006g
for 10 min. All the procedures for virus concentration were carried
out at 4uC. The concentrated virus preparations were aliquoted
and stored at 280uC for later experiments.
For cell infection, HUVEC were seeded onto glass cover slips
overnight to achieve 70–80% confluency. For assays using
chemical inhibitors, cells were pretreated with the inhibitors in
EBM-2 media for 1 hr prior to infection. The cells were then
inoculated with the virus preparation and incubated for the
indicated times in the presence of the inhibitors, fixed in 2%
paraformaldehyde and processed for immunostaining of KSHV
particles.
Antibodies and Chemical Inhibitors
A monoclonal antibody isotype IgG2a (clone 6A) to KSHV
small capsid protein (Orf65) was used to stain KSHV particles
[52]. Rabbit antibodies to EEA1, integrin b1, epsin, and eps15
were purchased from Abcam (Cambridge, MA). A rabbit
polyclonal antibody against LAMP1 was purchased from Sigma
Life Science (St. Louis, MO). Rabbit monoclonal antibodies
against c-Cbl, and pY700 c-Cbl were from Epitomics (Burlingame,
CA). A rabbit antibody against pY774 c-Cbl was from Cell
Signaling (Danvers, MA). Mouse monoclonal antibodies to Cbl
and Rabex-5 from Santa Cruz Biotechnology (Santa Cruz, CA)
were also used for Western-blot detection. A monoclonal antibody
against ubiquitin (P4D1) was from Santa Cruz. A rat anti-LANA
monoclonal antibody was purchased from Abcam (Cambridge,
MA).
Secondary antibodies AlexaFluor 568 goat-anti-mouse IgG1
and IgG2a, AlexaFluor 647 goat anti-mouse IgG1, AlexaFluor
488 goat anti-rabbit, and AlexaFluor 568 goat-anti-rat were from
Molecular Probes, Invitrogen (Carlsbad, CA). DAPI was from
BioChemika Ultra, Sigma.
Chemical inhibitors of proteasome function MG132 and EPOX
were purchased from Sigma. The inhibitor of E1 activating
enzyme UBEI-41 was obtained from Biogenova (Rockville, MD).
Chemical inhibitor of Src kinases pp1 was from Sigma. All
chemical inhibitor stock solutions were prepared according to the
manufacturer’s directions.
Transduction of shRNA Lentiviruses and Knock-Down of
c-Cbl and Rabex-5
c-Cbl, Rabex-5 and control shRNA lentivirus particles were
purchased from Santa Cruz. HUVEC grown to 40–50%
confluency in 6-well plates were pretreated with 5 mg/ml
polybrene for 30 min and infected with the specified lentivirus
particles. The infected cells were centrifuged at 2,000 rpm for 1 hr
to facilitate virus entry, and then incubated overnight. The virus
were removed on the second day, replaced with growth medium
and cultured for another 3 days before inoculation with KSHV or
lysed for Western-blotting detection of protein expression.
Microscopy
For immunofluorescence analysis, cells were incubated with
each primary antibody for 1 hr and then the appropriate
secondary antibody conjugated to Alexa Fluor 488, 568, or 647
(Invitrogen), all at 1:100 dilution. After washing with PBS, cells
were stained with DAPI and mounted onto glass slides with
FluorSave (Invitrogen). For quantification of entry and intracel-
lular trafficking of viral particles to the nuclei, images were
acquired using a Zeiss Axiovert 200M epifluorescence microscope
equipped with a 636 oil immersion objective (Carl Zeiss
Microimaging Inc., Thornwood, NY). Images were acquired for
at least 5 fields of view per coverslip to allow counting of Orf65+
viral particles docked at nuclei. For colocalization experiments,
images were acquired with an Olympus FV1000 scanning
confocal microscope equipped with a 606NA 1.42 oil immersion
objective (Olympus Life Science, Center Valley, PA). Z-stacks
were acquired at 0.25 mm per slice by sequentially scanning and in
8 bit color depth. Theoretical6and y axis resolution was 0.2 mm
and 0.2 mm, respectively. Olympus FV1000 software was used to
generate cross-sectional images and 3D-projection images (Olym-
pus Life Science). Fluorescence images were acquired sequentially,
using a 405-nm laser line with emission at 461 nm for DAPI; a
488-nm laser line with emission at 520 nm for Alexa Fluor 488;
and a 543-nm laser line with emission at 603 for Alexa Fluor 568,
and a 633-nm laser line with emission at 668 for AlexaFluor 647.
Voltage, gain, and offset were adjusted to prevent bleed-through.
Images were assembled using Adobe Photoshop CS3 version 10
(Adobe Systems Incorporated, San Jose, CA).
Three-Dimensional Colocalization Analysis
Z-stack images were first deconvolved with AutoQuant
deconvolution software using the adaptive point spread function
(Media Cybernetics, Inc., Bethesda, MD). Deconvolved images
were then analyzed with Imaris 3-D image analysis software
(Bitplane, Zurich, Switzerland). The threshold for each channel
was automatically calculated by the program using the Pearson’s
coefficient approach following orthogonal regression analysis on
the image’s scatterplot. To measure colocalization of endosomal
markers with KSHV particles through the x, y, and z planes, the
red channel (Orf65) was masked to create a new channel that
encapsulates the 500 nm region of the image around the center of
each viral particle. The masked channel was then used to
determine viral particle colocalization with each of the endosomal
markers (EEA1 or LAMP1) as well as for epsin, eps15, Rabex-5, c-
Cbl, Y700-c-Cbl, and Y774-c-Cbl. The same procedure was also
used to determine colocalization of viral particles with integrin b1
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germ agglutinin (WGA) in the far-red channel as well as viral
particles that were colocalized with nuclei stained with DAPI in
the blue channel. The total number of colocalized pixels (voxels in
3D) was counted for cells that had a minimum of five viral particles
per cell. To avoid an overrepresentation of colocalization, only
one colocalization event was counted for each viral particle.
Immunoblotting
To detect ubiquitin, HUVEC were pretreated for 1 hr with the
indicated chemical inhibitors of proteasome function then
inoculated with KSHV. Cell lysates were collected at the indicated
time post-infection and subjected to SDS-PAGE and immuno-
blotting to detect ubiquitin.
For analysis of c-Cbl phosphorylation, HUVEC were serum-
starved for 4 hr to reduce basal levels of c-Cbl phosphorylation,
and pretreated with increasing concentrations of PP1 analog for
1 hr prior to inoculation with KSHV. Cells treated with 100 ng/
ml EGF were included as a positive control for c-Cbl phosphor-
ylation. Lysates were collected and subjected to SDS-PAGE and
followed by immunoblot detection for total c-Cbl and the
indicated phosphorylated forms of c-Cbl.
Co-Immunoprecipitation Analysis
HUVEC cells were pretreated with DMSO or 5 mm UBEL-41
for 1 hr prior to inoculation with KSHV for 1 hr. Cells were
washed 3 times with cold PBS, harvested by centrifugation and
suspended in lysis buffer containing 20 mM Tris pH 7.4,
100 mM NaCl, 1% NP-40, 1 mM EDTA, 1 mM EGTA and
protease inhibitor cocktail (sigma). Lysates were sonicated at 25%
efficiency for 3 times, each for 5 sec, and centrifuged for 10 min
at 10,000 g at 4uC. The lysates were pre-cleared with protein G
beads for 1 hr and incubated with mouse anti-integrin b1 for
2h ra t4 uC. The protein G beads were used to precipitate the
immune complexes overnight 4uC with rotation, and the
immune complexes were analyzed by SDS-PAGE and West-
ern-blotting to detect ubiquitin.
Statistical Analysis
Results of analysis of viral particles trafficking to nuclei in the
presence of chemical inhibitors were expressed as the mean 6s.d.
Data were analyzed using t-test, analysis of variance, and Mann-
Whitney rank-sum tests where appropriate, with p,0.05 consid-
ered as significant using SigmaPlot 11.0 (Systat Software, Inc., San
Jose, CA). Cells bearing a minimum of five viral particles per cell
were included in the analysis. The distributions of viral particle
localization are summarized in box and whisker plots to represent
the median values (middle lines), the 75th and 25th percentiles
(opened boxes), and the 90th and 10th percentiles (short lines).
Outliers outside the 90th and 10th percentiles are represented as
black dots.
Supporting Information
Figure S1 Proteasome inhibitors MG132 and EPOX,
and E1 ligase inhibitor UBEI-41 do not affect the
numbers of cell-associated KSHV particles per cell.
HUVEC treated with DMSO, MG132, EPOX or UBEI-41 were
inoculated with KSHV for 4 hr, and examined for total numbers
of cell-associated viral particles. Box and whisker plots depict the
statistical analyses of the cellular localization of KSHV particles as
described in Figure 3. p-values ,0.05 are statistically significant.
(TIF)
Figure S2 Minimal colocalization of integrin b1 with
RRV, transferrin and cholera toxin B. To detect RRV
colocalization with integrin b1, cells infected with RRV-RFP for
4 hr were stained for RRV particles (red), integrin b1 (green) and
nuclei (blue). To detect colocalization or transferrin or cholera
toxin B with integrin b1, cells incubated with AlexaFluor 647-
transferrin (red) or AlexaFluor 647-cholera toxin B (red) for 1 hr
were stained for integrin b1 (green) and nuclei (blue). Images were
subjected to colocalization analysis.
(TIF)
Figure S3 KSHV particles are colocalized with E3 ligase
c-Cbl or its activated phosphorylated forms but, to a less
extent, with Rabex5. HUVEC infected with KSHV for 4 hr
were stained for KSHV particles (red), E3 ligase Rabex5 (green), c-
Cbl or its phosphorylated forms (pY700 or pY774) (green), and cell
nuclei (blue). Z-stack images were acquired and used for
colocalization analysis.
(TIF)
Figure S4 Knock-down of c-Cbl but not Rabex-5 pre-
vents KSHV infection of endothelial cells. HUVEC grown
on coverslips were mock treated or infected with c-Cbl, Rabex-5
or control lentivirus particles for 4 days, and infected with KSHV.
Cells were fixed and stained for LANA (red) and nuclei (blue) at
48 hpi. The results were analyzed and presented in Figure 9D. c-
Cbl shRNA but not Rabex-5 shRNA or control shRNA decreased
the numbers of LANA-positive cells.
(TIF)
Video S1 An overview of a HUVEC infected by KSHV.
HUVEC treated with DMSO were infected with KSHV for 4 hr,
stained for KSHV particles (red), cell membrane (white) and nuclei
(blue). Z-stack images were acquired with confocal laser-scanning
microscopy, and deconvolved. Imaris image analysis software was
used to generate 3-D contoured images and determine the
localizations of viral particles in relation to the cell membrane,
the cell interior, and the cell nucleus.
(MOV)
Video S2 An overview of a HUVEC infected by KSHV in
the presence of proteasome inhibitor MG132. HUVEC
treated with MG132 were processed as described in Video S1.
(MOV)
Video S3 An overview of a HUVEC infected by KSHV in
the presence of proteasome inhibitor EPOX. HUVEC
treated with EPOX were processed as described in Video S1.
(MOV)
Video S4 Formation of a KSHV-containing vesicle
during infection of HUVEC. A region of interest from Video
S1. The Imaris clipping plane function was used to reveal KSHV
particles enclosed within a membrane-bound vesicle.
(MOV)
Video S5 Association of KSHV particles with early
endosomal marker EEA1. HUVEC treated with DMSO were
infected with KSHV for 4 hr, stained for viral particles (red), EEA1
(green), and nuclei (blue). Z-stacks were deconvolved and Imaris
image analysis software was used togenerate 3-Dcontouredimages.
(MOV)
Video S6 Association of KSHV particles with early
endosomal marker EEA1 in the presence of proteasome
inhibitor MG132. HUVEC treated with MG132 were pro-
cessed as described in Video S5.
(MOV)
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endosomal marker EEA1 in the presence of proteasome
inhibitor EPOX. HUVEC treated with EPOX were processed
as described in Video S5.
(MOV)
Video S8 Formation of KSHV-containing EEA1+ early
endosomes during infection of HUVEC. A region of interest
from Video S5. The Imaris clipping plane function was used to
reveal KSHV particles enclosed within an EEA1+ compartment.
(MOV)
Video S9 Association of KSHV particles with late
endosomal marker LAMP1. HUVEC treated with DMSO
were infected with KSHV for 4 hr, stained for KSHV particles
(red), LAMP1 (green), and nuclei (blue). Z-stacks were decon-
volved and Imaris image analysis software was used to generate 3-
D contoured images.
(MOV)
Video S10 Association of KSHV particles with late
endosomal marker LAMP1 in the presence of protea-
some inhibitor MG132. HUVEC treated with MG132 were
processed as described in Video S9.
(MOV)
Video S11 Association of KSHV particles with late
endosomal marker LAMP1 in the presence of protea-
some inhibitor EPOX. HUVEC treated with EPOX were
processed as described in Video S9.
(MOV)
Video S12 Formation of KSHV-containing LAMP1+ late
endosomes during infection of HUVEC. A region of interest
from Video S9. The Imaris clipping plane function was used to
reveal KSHV particles enclosed within an LAMP1+ vesicle.
(MOV)
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